Journal of Turkish Clinical Biochemistry

The official publication of Turkish Society of Clinical Biochemistry

Diamond OA
No APCs
First Decision
30 Days
Indexed In
TR Dizin
Original Research
April 01, 2009
JTCB. 2009 Apr 1; 7 (1) : 007-015

Total and Lipid-Bound Sialic Acid Levels in Experimental Myocardial Infarction

1 Trakya Üniversitesi Tıp Fakültesi, Biyokimya Anabilim Dalı, Edirne
2 Trakya Üniversitesi Tıp Fakültesi, Patoloji Anabilim Dalı

Abstract

Objective: Sialic acid, known as a risk factor for coronary heart disease is also elevated in serum after myocardial infarction. Because acute myocardial infarction generally develops on the basis of atherosclerotic heart disease, the effect of experimental myocardial infarction in which a possible sialic acid elevation resulted from atherosclerosis is eliminated, on serum total and lipid-bound sialic acid levels was investigated in this study.

Material and Methods: Myocardial infarction was produced in male albino rats of Wistar strain with 150 mg/kg of isoproterenol (ISO) administered intraperitoneally twice at an interval of 24h. Existence of experimental infarction was confirmed by histopathological changes and the elevation of troponin I and creatine kinase-MB. Th e levels of serum total and lipid-bound sialic acid were determined by the methods of Warren and Katopodis, respectively.

Results: Isoproterenol treatment caused a significant elevation in serum troponin I and creatine kinase-MB levels of rats. Serum total (p=0.000) and lipid-bound sialic acid (p=0.000) levels were also significantly elevated post-infarction. However, there was no significant correlation between total or lipid-bound sialic acid and cardiac injury markers.

Conclusion: Myocardial infarction induced by isoproterenol causes an elevation in serum total and lipid-bound sialic acid levels by a mechanism independent from the pathogenesis of atherosclerosis.

Citation

Kazezoğlu, Cemal, Ufuk Usta, and Selma Süer Gökmen. 2009. “Total and Lipid-Bound Sialic Acid Levels in Experimental Myocardial Infarction”. Journal of Turkish Clinical Biochemistry 7 (1):007-015. https://turkclinbiochem.org/index.php/pub/article/view/112.

Publish with JTCB

Diamond Open Access

Fully Diamond OA with no APCs and no submission fees. Your research is freely available to readers worldwide from the day it publishes.

30-Day First Decision

Double-blind peer review from an active editorial team returns a first decision in about 30 days, keeping your manuscript moving.

Global Platform

Backed by the Turkish Society of Clinical Biochemistry, JTCB welcomes submissions from researchers worldwide and reaches an international laboratory audience.

Focused Laboratory Scope

Method validation, analyzer comparisons, reference intervals, quality indicators, preanalytical studies, and instructive clinical case reports.

Credible and Discoverable

All manuscripts publish in English and follow ICMJE and COPE guidelines, with Crossref DOIs and TR Dizin indexing ensuring global discoverability.